Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955324 | 0.84 | ALDH1A1 (0.46) | KDRLOXL2 | |
| SCHEMBL18404809 | 0.82 | CYP2A6 (0.59) | KDR | |
| SCHEMBL3176189 | 0.81 | MEN1 (0.44) | LOXL2SLC6A3KMT2A | |
| SCHEMBL9955397 | 0.81 | HSD17B1 (0.47) | KDRLOXL2CNR1KMT2A | |
| SCHEMBL9954919 | 0.81 | HSD17B1 (0.51) | KDRLOXL2CNR1KMT2A | |
| SCHEMBL13524910 | 0.81 | LIMK1 (0.47) | KDRCNR1LMNA | |
| SCHEMBL1748119 | 0.79 | L3MBTL1 (0.41) | KDRSLC6A3LMNA | |
| SCHEMBL1747939 | 0.78 | RAB9A (0.43) | LMNA | |
| SCHEMBL38651038 | 0.78 | FFAR2 (0.41) | KDRLOXL2ERCC5FEN1CNR1 | |
| SCHEMBL15090492 | 0.77 | HSD17B1 (0.58) | KDRLOXL2ERCC5FEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-26 | — | — | US | disclosed |
| EP-4392410-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS | The University of British Columbia (CA) | 2024-07-03 | — | — | EP | disclosed |
| CN-118063442-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| CN-111491920-B | Antagonists of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2024-01-30 | — | — | CN | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885LOXL2 485/4885ERCC5 3512/4885 |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | KDR 3831/4885LOXL2 3226/4885ERCC5 3391/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | KDR 2722/4885LOXL2 3447/4885ERCC5 3127/4885 |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | KDR 3831/4885LOXL2 3226/4885ERCC5 3391/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885LOXL2 485/4885ERCC5 3512/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885LOXL2 485/4885ERCC5 3512/4885 |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM3, CHRM4, CHRM2 | KDR 1888/4885LOXL2 3589/4885ERCC5 2616/4885 |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | BRDT, BRPF3, BRIX1 | KDR 2093/4885LOXL2 1574/4885ERCC5 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.